Late Stage Mature Pre IPO Unicorns -

Infectious disease biotech Alopexx files for a $17 million IPO

By Renaissance Capital, Alopexx, a Phase 2 biotech developing immune therapies for bacterial, fungal, and parasitic infections, filed on Monday with the SEC to raise up to $17 million in an initial public offering. The company is developing novel immune therapeutics for the prevention, treatment and mitigation of bacterial, fungal, and parasitic infections that express[…]